Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Lockheed Martin Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Lockheed Martin Corporation trades at $517.1 (market cap $118.74B). The key difference: Lockheed Martin Corporation is far larger — about 14.8× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Lockheed Martin Corporation pays a 2.68% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | LMT | |
|---|---|---|
Market Cap | $8.04B | $118.74B |
Sector | Health | Industrials |
52-Week High | $339.75 | $676.70 |
52-Week Low | $241.71 | $410.74 |
Enterprise Value | $7.85B | $137.54B |
Dividend Yield | — | 2.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Lockheed Martin (LMT) trades at $520.68, down 0.49% on the day, with a bearish technical signal and mixed earnings history. The company reported $75.05B in 2025 revenue and a net income margin of 6.38%, while maintaining a $194B backlog as of Q4 2025 (24/7 Wall Street, 2026-07-13). Analyst consensus is bullish with a $614 price target, supported by strong defense spending trends.
Outlook remains positive due to robust demand from global defense budgets, but risks include execution challenges and margin pressure. The stock offers value with a P/E of 25.21 and dividend yield near 2.66%, though recent EPS misses warrant caution. Institutional sentiment favors long-term growth amid geopolitical tensions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
